News | June 25, 2007

July 1 Marks the Launch of CMS Physician Quality Reporting Initiative

June 26, 2007 - Physicians who report quality measures for care delivered to Medicare beneficiaries July 1–December 31, 2007 may receive an additional 1.5 percent incentive payment, subject to a bonus payment cap.

Voluntary participants must report a minimum of three quality measures on at least 80 percent of the cases for which that quality measure is reportable. If it is determined that reporting occurred less than 80 percent of the time for any one of the measures, the physician would be ineligible for the incentive payment.

Quality measures within the 2007 Physician Quality Reporting Initiative (PQRI) are adopted or endorsed by a consensus organization such as the AQA Alliance, the Physician Consortium, or National Quality Forum (NQF). HRS' Quality Improvement Task Force, Chaired by Stephen C. Hammill, M.D., and Sana Alkhatib, M.D., has been working on efforts to include reimbursement codes routinely used by HRS Membership into this initiative. 74 quality measures have been announced with specific reimbursement codes linked to each quality measure.

Members of the Heart Rhythm Society have the opportunity to report on:

* ACE or ARB therapy for heart failure patients with Left Ventricular Systolic Dysfunction (LVSD)
* Antiplatelet therapy prescribed for Coronary Artery Disease (CAD) patients
* Beta-blocker therapy prescribed for CAD patients with prior Myocardial Infarction (MI)
* Beta-blocker therapy prescribed for heart failure patients with LVSD
* Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
* Perioperative Care: Discontinuation of Prophylactic Antibiotic

Reporting is claims-based. CPT Category II codes (or temporary G-codes where CPT Category II codes are not yet available) will be used for reporting quality data. Quality data codes, which supply the measure numerator, must be reported on the same claim as the payment codes, which supply the measure denominator. CMS will provide new information and educational opportunities in the near future.

For more information: www.hrsonline.org.

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init